Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Nov;35(11):2447–2449. doi: 10.1128/aac.35.11.2447

Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

E J Goldstein 1, D M Citron 1
PMCID: PMC245404  PMID: 1804024

Abstract

The in vitro activities of ofloxacin alone and in combination with metronidazole against 177 anaerobic bacteria isolated from intra-abdominal infections, as determined by broth microdilution, showed that some Bacteroides fragilis strains were susceptible and that most other B. fragilis group species strains were resistant to ofloxacin. Isolates of other anaerobic species and genera, including those causing female genital tract disease, were generally susceptible to ofloxacin. Ofloxacin in combination with metronidazole usually showed an additive or indifferent interaction but no antagonism.

Full text

PDF
2447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edlund C., Lindqvist L., Nord C. E. Norfloxacin binds to human fecal material. Antimicrob Agents Chemother. 1988 Dec;32(12):1869–1874. doi: 10.1128/aac.32.12.1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fuchs P. C. In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status. Am J Med. 1989 Dec 29;87(6C):10S–13S. [PubMed] [Google Scholar]
  3. Goldstein E. J., Citron D. M., Corrado M. L. Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract. Am J Med. 1987 Jun 26;82(6B):84–87. doi: 10.1016/0002-9343(87)90625-5. [DOI] [PubMed] [Google Scholar]
  4. Grüneberg R. N., Felmingham D., O'Hare M. D., Robbins M. J., Perry K., Wall R. A., Ridgway G. L. The comparative in-vitro activity of ofloxacin. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):9–19. doi: 10.1093/jac/22.supplement_c.9. [DOI] [PubMed] [Google Scholar]
  5. King A., Shannon K., Phillips I. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. J Antimicrob Chemother. 1985 May;15(5):551–558. doi: 10.1093/jac/15.5.551. [DOI] [PubMed] [Google Scholar]
  6. Leigh D. A., Walsh B., Harris K., Hancock P., Travers G. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):115–125. doi: 10.1093/jac/22.supplement_c.115. [DOI] [PubMed] [Google Scholar]
  7. Monk J. P., Campoli-Richards D. M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Apr;33(4):346–391. doi: 10.2165/00003495-198733040-00003. [DOI] [PubMed] [Google Scholar]
  8. Whiting J. L., Cheng N., Chow A. W. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria. Antimicrob Agents Chemother. 1987 Sep;31(9):1379–1382. doi: 10.1128/aac.31.9.1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Winston D. J., Ho W. G., Bruckner D. A., Gale R. P., Champlin R. E. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990 Jan;88(1):36–42. doi: 10.1016/0002-9343(90)90125-w. [DOI] [PubMed] [Google Scholar]
  10. van Saene H. K., Lemmens S. E., van Saene J. J. Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):127–134. doi: 10.1093/jac/22.supplement_c.127. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES